People visit the booth of Chinese firm Mindray during the Africa Health ExCon in Cairo, Egypt, on June 6, 2022. (Xinhua/Ahmed Gomaa)
BEIJING, Aug. 1 (Xinhua) -- Chinese medical device provider Mindray announced on Monday to acquire 75 percent stake of DiaSys Diagnostic Systems GmbH from Gorka Holding GmbH, through its wholly-owned subsidiaries, reported Xinhua-run China Securities Journal.
It is learned that the acquisition is valued at approximately 115 million euros (about 128.8 million U.S. dollars).
After completion of the transaction, Mindray and Gorka Holding GmbH will jointly invest an additional 40 million euros (about 44.8 million U.S. dollars) in DiaSys in proportion to support DiaSys' future business development.
Founded in 1991 and headquartered in Holzheim, Germany, DiaSys is a world-renowned brand in vitro diagnostic with more than 30 years' experience in the field of biochemical reagents, quality control and calibration products.
"We are very pleased to see this collaboration come to fruition, as Mindray's and DiaSys' businesses strongly complement each other. Through this acquisition, Mindray will effectively improve its overseas supply chain platform and help its vitro diagnostic business reach more customers," said Wu Hao, president of Mindray.
(Edited by Bao Nuomin with Xinhua Silk Road, baonuomin@xinhua.org)
A single purchase
